{
    "nctId": "NCT00903162",
    "briefTitle": "Extended Endocrine Therapy for Premenopausal Women With Breast Cancer",
    "officialTitle": "Extended Endocrine Therapy for Premenopausal Women With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 17,
    "primaryOutcomeMeasure": "Tolerability at One Year of Ovarian Function Suppression (OFS) Using Leuprolide and Letrozole.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women 18 years of age or older\n* History of invasive ER+ or PR+ breast cancer treated with at least 4.5 years of tamoxifen\n* No current evidence of recurrent invasive disease or metastatic disease. Patients may have a history of bilateral breast cancer\n* Premenopausal (estradiol level in premenopausal range, \\>20pg/ml, within the prior 28 days)\n* Liver function tests and creatinine \\<2.5 times the upper limit of normal within the 28 days prior to enrollment\n* ECOG Performance Status 0-1\n* Must agree to use non-hormonal contraception (condoms, diaphragm, IUD, sterilization, abstinence, etc) and no other hormonal therapy during trial and until 3 months after letrozole is stopped\n* Negative pregnancy test within 14 days prior to enrollment\n* Patient must be able to speak, read and write in English\n\nExclusion Criteria:\n\n* Previous treatment with an oral or IV bisphosphonate in the prior two years\n* History of cancer other than breast cancer within 5 years excluding basal/squamous cell skin carcinoma in situ of the cervix\n* Women with evidence of current local recurrence or metastatic breast cancer\n* Pregnant women\n* Nursing women\n* Women who are currently taking tamoxifen and are unwilling to stop this medication\n* Women with a known deleterious BRCA 1 or BRCA 2 mutation",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}